Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?

The molecular and cell determinants that modulate immune checkpoint (ICI) efficacy in lung cancer are still not well understood. However, there is a necessity to select those patients that will most benefit from these new treatments. Recent studies suggest the presence and/or the relative balance of...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Marta Gascón, Dolores Isla, Mara Cruellas, Eva M. Gálvez, Rodrigo Lastra, Maitane Ocáriz, José Ramón Paño, Ariel Ramírez, Andrea Sesma, Irene Torres-Ramón, Alfonso Yubero, Julián Pardo, Luis Martínez-Lostao
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2020-06-01
Rangatū:	Cells
Ngā marau:	biomarkers lung cancer immune cells in cancer tumor microenvironment immune checkpoints inhibitors
Urunga tuihono:	https://www.mdpi.com/2073-4409/9/6/1525
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!